Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Comparison of FDG-PET/CT and CT for Treatment Evaluation of Patients With Unresectable Malignant Pleural Mesothelioma

Oncotarget

July 15, 2024
PRESS RELEASE: On June 20, 2024, a new research paper was published in Oncotarget, entitled, “Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.” continue reading »

AI for Improved PET/CT Attenuation Correction in Prostate Cancer Imaging

Oncotarget

July 11, 2024
In this new study, researchers investigated an artificial intelligence (AI) tool that produces attenuation-corrected PET images while reducing radiation exposure for patients. continue reading »

Targeting ABC Transporters in PDAC – Past, Present, or Future?

News

July 10, 2024
PRESS RELEASE: On June 20, 2024, a new editorial was published in Oncotarget, entitled, “Targeting ABC transporters in PDAC – past, present, or future?” continue reading »

Regorafenib Synergizes With TAS102 Against Multiple Gastrointestinal Cancers

News

July 9, 2024
PRESS RELEASE: On July 2, 2024, a new research paper was published in Oncotarget, entitled, “Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers [...].” continue reading »

Editorial: Genomics Has More to Reveal

News

July 2, 2024
PRESS RELEASE: On June 20, 2024, a new editorial was published in Oncotarget, entitled, “Genomics has more to reveal.” continue reading »